Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 2
2016 7
2017 11
2018 10
2019 9
2020 4
2021 8
2022 7
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab-induced thyroid dysfunction.
Tanaka R, Fujisawa Y, Maruyama H, Nakamura Y, Yoshino K, Ohtsuka M, Fujimoto M. Tanaka R, et al. Among authors: yoshino k. Jpn J Clin Oncol. 2016 Jun;46(6):575-9. doi: 10.1093/jjco/hyw036. Epub 2016 Mar 23. Jpn J Clin Oncol. 2016. PMID: 27012985
Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
Fujisawa Y, Namikawa K, Yoshino K, Kiniwa Y, Ito T, Kato H, Matsushita S, Hoashi T, Nakamura Y, Yoshikawa S, Miyagawa T, Asai J, Matsuya T, Fukushima S, Kato J, Takenouchi T, Uchi H, Masuzawa M, Yanagi T, Maekawa T. Fujisawa Y, et al. Among authors: yoshino k. Br J Dermatol. 2023 Jul 17;189(2):223-250. doi: 10.1093/bjd/ljad114. Br J Dermatol. 2023. PMID: 37017027 No abstract available.
Postoperative adjuvant therapy for 120 patients with melanoma, including acral and mucosal subtypes: a multicentre, observational study of 2-year follow-up results.
Muto Y, Kambayashi Y, Kato H, Fukushima S, Ito T, Maekawa T, Shoichiro I, Uchi H, Matsushita S, Yamamoto Y, Yoshino K, Fujisawa Y, Amagai R, Ohuchi K, Hashimoto A, Asano Y, Fujimura T. Muto Y, et al. Among authors: yoshino k. Br J Dermatol. 2023 Sep 15;189(4):476-478. doi: 10.1093/bjd/ljad183. Br J Dermatol. 2023. PMID: 37243542 No abstract available.
Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, Isei T, Takenouchi T, Kato H, Mizuhashi S, Fukushima S, Yamamoto Y, Inozume T, Fujisawa Y, Yamasaki O, Nakamura Y, Asai J, Maekawa T, Funakoshi T, Matsushita S, Nakano E, Oashi K, Kato J, Uhara H, Miyagawa T, Uchi H, Hatta N, Tsutsui K, Maeda T, Matsuya T, Yanagisawa H, Muto I, Okumura M, Ogata D, Yamazaki N. Namikawa K, et al. Among authors: yoshino k. Cancer Med. 2023 Sep;12(17):17967-17980. doi: 10.1002/cam4.6438. Epub 2023 Aug 16. Cancer Med. 2023. PMID: 37584204 Free PMC article.
CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.
Kurokawa M, Kurokawa R, Hagiwara A, Gonoi W, Harayama S, Koizumi K, Yoshino K, Hishima T, Baba A, Ota Y, Abe O, Takaki Y. Kurokawa M, et al. Among authors: yoshino k. Abdom Radiol (NY). 2021 Jul;46(7):3033-3043. doi: 10.1007/s00261-021-02986-0. Epub 2021 Feb 26. Abdom Radiol (NY). 2021. PMID: 33638055
Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study.
Inozume T, Namikawa K, Kato H, Yoshikawa S, Kiniwa Y, Yoshino K, Mizuhashi S, Ito T, Takenouchi T, Matsushita S, Fujisawa Y, Matsuzawa T, Sugihara S, Asai J, Kitagawa H, Maekawa T, Isei T, Yasuda M, Yamazaki N, Uhara H, Nakamura Y. Inozume T, et al. Among authors: yoshino k. J Dermatol Sci. 2023 Apr;110(1):19-26. doi: 10.1016/j.jdermsci.2023.03.008. Epub 2023 Mar 31. J Dermatol Sci. 2023. PMID: 37045720
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, Fujisawa Y, Matsushita S, Amagai R, Yamazaki E, Takahashi M, Tamabuchi E, Hashimoto A, Kambayashi Y, Yamazaki N, Miyata T, Asano Y. Fujimura T, et al. Among authors: yoshino k. Exp Dermatol. 2024 Jan;33(1):e14976. doi: 10.1111/exd.14976. Epub 2023 Nov 9. Exp Dermatol. 2024. PMID: 37946551
57 results